Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Total Non-Current Liabilities (2021 - 2026)

Cingulate's (CINGW) quarterly Total Non-Current Liabilities came in at $968455.0 in Q2 2026, down 56.99% quarter-over-quarter from $2.3 million in Q4 2025.

Analysis

Cingulate (CINGW) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Cingulate (CINGW) has reported Total Non-Current Liabilities for 6 consecutive years, with $968455.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities changed N/A year-over-year to $968455.0; the trailing twelve-month figure through Jun 2026 stood at $968455.0 (changed N/A YoY), and the FY2025 full-year result was $2.3 million, down 7.6% from the prior year.
  • Total Non-Current Liabilities slipped to $968455.0 in Q2 2026 per CINGW's latest filing, from $2.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.4 million in Q4 2024 and bottomed at $33145.0 in Q1 2024.
  • Historically, Total Non-Current Liabilities has averaged $834527.8 across 5 years, with a median of $557188.5 in 2022.
  • The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities sank 92.16% in 2024, then soared 2686.84% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $510235.0 in 2022, then sank by 73.52% to $135099.0 in 2023, then soared by 1703.77% to $2.4 million in 2024, then declined by 7.6% to $2.3 million in 2025, then plunged by 56.99% to $968455.0 in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $968455.0, $2.3 million, and $1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 644.46 Bn 623.70 Bn 17.26 Bn 105.99 Bn
2 AbbVie 440.11 Bn 433.54 Bn 12.70 Bn 106.45 Bn
3 Merck 365.04 Bn 357.90 Bn 12.21 Bn 16.16 Bn
4 Novartis Ag 266.82 Bn 259.13 Bn 11.24 Bn 48.34 Bn
5 Pfizer 159.14 Bn 147.45 Bn 10.94 Bn 100.86 Bn
6 Sanofi 52.47 Bn 45.09 Bn 10.79 Bn 32.04 Bn
7 Revolution Medicines 44.26 Bn 44.26 Bn - 1.53 Bn
8 Incyte 25.32 Bn 20.79 Bn 1.57 Bn 1.40 Bn
9 United Therapeutics 21.46 Bn 18.80 Bn 683.80 Mn 607.80 Mn
10 Cingulate 100,214.03 100,214.03 - 968,455.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 968,455.00
Dec 31, 2025 2.25 Mn
Sep 30, 2025 1.16 Mn
Mar 31, 2025 923,698.00
Dec 31, 2024 2.44 Mn
Mar 31, 2024 33,145.00
Dec 31, 2023 135,099.00
Sep 30, 2023 234,160.00
Jun 30, 2023 331,066.00
Mar 31, 2023 422,802.00
Dec 31, 2022 510,235.00
Sep 30, 2022 604,142.00
Dec 31, 2021 866,037.00